Cargando…
Markers of Thrombogenesis and Fibrinolysis and Their Relation to Inflammation and Endothelial Activation in Patients with Idiopathic Pulmonary Arterial Hypertension
BACKGROUND: Chronic anticoagulation is a standard of care in idiopathic pulmonary arterial hypertension (IPAH). However, hemostatic abnormalities in this disease remain poorly understood. Therefore, we aimed to study markers of thrombogenesis and fibrinolysis in patients with IPAH. METHODS: We studi...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3847115/ https://www.ncbi.nlm.nih.gov/pubmed/24312667 http://dx.doi.org/10.1371/journal.pone.0082628 |
_version_ | 1782293542841876480 |
---|---|
author | Kopeć, Grzegorz Moertl, Deddo Steiner, Sabine Stępień, Ewa Mikołajczyk, Tomasz Podolec, Jakub Waligóra, Marcin Stępniewski, Jakub Tomkiewicz-Pająk, Lidia Guzik, Tomasz Podolec, Piotr |
author_facet | Kopeć, Grzegorz Moertl, Deddo Steiner, Sabine Stępień, Ewa Mikołajczyk, Tomasz Podolec, Jakub Waligóra, Marcin Stępniewski, Jakub Tomkiewicz-Pająk, Lidia Guzik, Tomasz Podolec, Piotr |
author_sort | Kopeć, Grzegorz |
collection | PubMed |
description | BACKGROUND: Chronic anticoagulation is a standard of care in idiopathic pulmonary arterial hypertension (IPAH). However, hemostatic abnormalities in this disease remain poorly understood. Therefore, we aimed to study markers of thrombogenesis and fibrinolysis in patients with IPAH. METHODS: We studied 27 consecutive patients (67% female) with IPAH aged 50.0 years (IQR: 41.0 - 65.0) and 16 controls without pulmonary hypertension. Prothrombin fragment 1+2 (F1+2) and thrombin-antithrombin (TAT) complexes were measured to assess thrombogenesis; tissue-type plasminogen activator (tPA) antigen and plasmin-anti-plasmin complex to characterize activation of fibrinolysis; plasminogen activator inhibitor 1 (PAI-1) to measure inhibition of fibrinolysis; and endothelin-1 (ET-1) and interleukin-6 (IL-6) to assess endothelial activation and systemic inflammation, respectively. In addition, in treatment-naive IPAH patients these markers were assessed after 3 months of PAH-specific therapies. RESULTS: TPA (10.1[6.8-15.8] vs 5.2[3.3-7.3] ng/ml, p<0.001), plasmin-anti-plasmin (91.5[60.3-94.2] vs 55.8[51.1-64.9] ng/ml, p<0.001), IL-6 (4.9[2.5-7.9] vs 2.1[1.3-3.8] pg/ml, p=0.001) and ET-1 (3.7 [3.3-4.5] vs 3.4[3.1-3.5], p= 0.03) were higher in patients with IPAH than in controls. In IPAH patients plasmin-anti-plasmin and tPA correlated positively with IL-6 (r=0.39, p=0.04 and r=0.63, p<0.001, respectively) and ET-1 (r=0.55, p=0.003 and r=0.59, p=0.001, respectively). No correlation was found between tPA or plasmin-anti-plasmin and markers of thrombogenesis. Plasmin-anti-plasmin decreased after 3 months of PAH specific therapy while the other markers remained unchanged. CONCLUSIONS: In the present study we showed that markers of fibrynolysis were elevated in patients with IPAH however we did not find a clear evidence for increased thrombogenesis in this group of patients. Fibrinolysis, inflammation, and endothelial activation were closely interrelated in IPAH. |
format | Online Article Text |
id | pubmed-3847115 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-38471152013-12-05 Markers of Thrombogenesis and Fibrinolysis and Their Relation to Inflammation and Endothelial Activation in Patients with Idiopathic Pulmonary Arterial Hypertension Kopeć, Grzegorz Moertl, Deddo Steiner, Sabine Stępień, Ewa Mikołajczyk, Tomasz Podolec, Jakub Waligóra, Marcin Stępniewski, Jakub Tomkiewicz-Pająk, Lidia Guzik, Tomasz Podolec, Piotr PLoS One Research Article BACKGROUND: Chronic anticoagulation is a standard of care in idiopathic pulmonary arterial hypertension (IPAH). However, hemostatic abnormalities in this disease remain poorly understood. Therefore, we aimed to study markers of thrombogenesis and fibrinolysis in patients with IPAH. METHODS: We studied 27 consecutive patients (67% female) with IPAH aged 50.0 years (IQR: 41.0 - 65.0) and 16 controls without pulmonary hypertension. Prothrombin fragment 1+2 (F1+2) and thrombin-antithrombin (TAT) complexes were measured to assess thrombogenesis; tissue-type plasminogen activator (tPA) antigen and plasmin-anti-plasmin complex to characterize activation of fibrinolysis; plasminogen activator inhibitor 1 (PAI-1) to measure inhibition of fibrinolysis; and endothelin-1 (ET-1) and interleukin-6 (IL-6) to assess endothelial activation and systemic inflammation, respectively. In addition, in treatment-naive IPAH patients these markers were assessed after 3 months of PAH-specific therapies. RESULTS: TPA (10.1[6.8-15.8] vs 5.2[3.3-7.3] ng/ml, p<0.001), plasmin-anti-plasmin (91.5[60.3-94.2] vs 55.8[51.1-64.9] ng/ml, p<0.001), IL-6 (4.9[2.5-7.9] vs 2.1[1.3-3.8] pg/ml, p=0.001) and ET-1 (3.7 [3.3-4.5] vs 3.4[3.1-3.5], p= 0.03) were higher in patients with IPAH than in controls. In IPAH patients plasmin-anti-plasmin and tPA correlated positively with IL-6 (r=0.39, p=0.04 and r=0.63, p<0.001, respectively) and ET-1 (r=0.55, p=0.003 and r=0.59, p=0.001, respectively). No correlation was found between tPA or plasmin-anti-plasmin and markers of thrombogenesis. Plasmin-anti-plasmin decreased after 3 months of PAH specific therapy while the other markers remained unchanged. CONCLUSIONS: In the present study we showed that markers of fibrynolysis were elevated in patients with IPAH however we did not find a clear evidence for increased thrombogenesis in this group of patients. Fibrinolysis, inflammation, and endothelial activation were closely interrelated in IPAH. Public Library of Science 2013-12-02 /pmc/articles/PMC3847115/ /pubmed/24312667 http://dx.doi.org/10.1371/journal.pone.0082628 Text en © 2013 Kopeć et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited. |
spellingShingle | Research Article Kopeć, Grzegorz Moertl, Deddo Steiner, Sabine Stępień, Ewa Mikołajczyk, Tomasz Podolec, Jakub Waligóra, Marcin Stępniewski, Jakub Tomkiewicz-Pająk, Lidia Guzik, Tomasz Podolec, Piotr Markers of Thrombogenesis and Fibrinolysis and Their Relation to Inflammation and Endothelial Activation in Patients with Idiopathic Pulmonary Arterial Hypertension |
title | Markers of Thrombogenesis and Fibrinolysis and Their Relation to Inflammation and Endothelial Activation in Patients with Idiopathic Pulmonary Arterial Hypertension |
title_full | Markers of Thrombogenesis and Fibrinolysis and Their Relation to Inflammation and Endothelial Activation in Patients with Idiopathic Pulmonary Arterial Hypertension |
title_fullStr | Markers of Thrombogenesis and Fibrinolysis and Their Relation to Inflammation and Endothelial Activation in Patients with Idiopathic Pulmonary Arterial Hypertension |
title_full_unstemmed | Markers of Thrombogenesis and Fibrinolysis and Their Relation to Inflammation and Endothelial Activation in Patients with Idiopathic Pulmonary Arterial Hypertension |
title_short | Markers of Thrombogenesis and Fibrinolysis and Their Relation to Inflammation and Endothelial Activation in Patients with Idiopathic Pulmonary Arterial Hypertension |
title_sort | markers of thrombogenesis and fibrinolysis and their relation to inflammation and endothelial activation in patients with idiopathic pulmonary arterial hypertension |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3847115/ https://www.ncbi.nlm.nih.gov/pubmed/24312667 http://dx.doi.org/10.1371/journal.pone.0082628 |
work_keys_str_mv | AT kopecgrzegorz markersofthrombogenesisandfibrinolysisandtheirrelationtoinflammationandendothelialactivationinpatientswithidiopathicpulmonaryarterialhypertension AT moertldeddo markersofthrombogenesisandfibrinolysisandtheirrelationtoinflammationandendothelialactivationinpatientswithidiopathicpulmonaryarterialhypertension AT steinersabine markersofthrombogenesisandfibrinolysisandtheirrelationtoinflammationandendothelialactivationinpatientswithidiopathicpulmonaryarterialhypertension AT stepienewa markersofthrombogenesisandfibrinolysisandtheirrelationtoinflammationandendothelialactivationinpatientswithidiopathicpulmonaryarterialhypertension AT mikołajczyktomasz markersofthrombogenesisandfibrinolysisandtheirrelationtoinflammationandendothelialactivationinpatientswithidiopathicpulmonaryarterialhypertension AT podolecjakub markersofthrombogenesisandfibrinolysisandtheirrelationtoinflammationandendothelialactivationinpatientswithidiopathicpulmonaryarterialhypertension AT waligoramarcin markersofthrombogenesisandfibrinolysisandtheirrelationtoinflammationandendothelialactivationinpatientswithidiopathicpulmonaryarterialhypertension AT stepniewskijakub markersofthrombogenesisandfibrinolysisandtheirrelationtoinflammationandendothelialactivationinpatientswithidiopathicpulmonaryarterialhypertension AT tomkiewiczpajaklidia markersofthrombogenesisandfibrinolysisandtheirrelationtoinflammationandendothelialactivationinpatientswithidiopathicpulmonaryarterialhypertension AT guziktomasz markersofthrombogenesisandfibrinolysisandtheirrelationtoinflammationandendothelialactivationinpatientswithidiopathicpulmonaryarterialhypertension AT podolecpiotr markersofthrombogenesisandfibrinolysisandtheirrelationtoinflammationandendothelialactivationinpatientswithidiopathicpulmonaryarterialhypertension |